ABSTRACT
Dolutegravir is a second-generation HIV integrase strand transfer inhibitor (INSTI) and the most recent antiretroviral approved for treatment of HIV-1 infection. Dolutegravir in combination with two nucleoside reverse transcriptase inhibitors is one of the preferred regimens recommended by the Department of Health and Human Services HIV treatment guidelines for treatment-naive adults and adolescents. This recommendation is based on clinical trial data where dolutegravir demonstrated superiority compared with guideline preferred regimens containing efavirenz and ritonavir-boosted darunavir and noninferiority compared with first-generation INSTI, raltegravir. Dolutegravir also demonstrated superiority when compared with raltegravir in treatment-experienced, integrase-naive patients and clinical efficacy in patients with resistance to first-generation INSTIs. Overall, dolutegravir has demonstrated excellent tolerability, limited drug interactions, minimal drug resistance and once-daily dosing for treatment-naive patients.
Financial & competing interests disclosure
Blake Max’s spouse is employed as a regional medical scientist for ViiV Healthcare, which manufactures dolutegravir. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.